Results

1–10 of 314 results for trial

Elevatum Study Design and Rationale: A Phase 4 Trial of Faricimab (VABYSMO) in Underrepresented Patients With Diabetic Macular Edema
Joseph M. Coney, MD, FASRS
Annual Meeting Talks
2023
Geographic Trends in the Recruitment of Participants of Racial and Ethnic Minorities for Diabetic Retinopathy-Related Clinical Trials
Vivienne S. Hau, MD, PhD
Annual Meeting Talks
2023
Defining a 'Strong' and 'Weak' Response to Anti-VEGF Treatment CI-DME: Retrospective Analysis of 3 DRCR Retina Network Clinical Trials
Sharon D. Solomon, MD
Annual Meeting Talks
2023
Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy: An Anchored Matching-Adjusted Indirect Comparison of the Phase 3 Trials
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2023
Effect of Pegcetacoplan on Photoreceptor and Retinal Pigment Epithelium Integrity in Geographic Atrophy in the Phase 3 Trials and GALE Extension Study
Ursula M. Schmidt-Erfurth, MD
Annual Meeting Talks
2023
Subgroup Analyses of the Phase 1 DAVIO Trial of EYP-1901 Showing Reduced Treatment Burden in Wet Age-related Macular Degeneration
Philip P Storey, MD, MPH
Annual Meeting Talks
2023
ENVISION Trial 24-Week Data: Phase 2 Study of UBX1325, a New Senolytic Agent for Patients With Wet AMD
Raj K. Maturi, MD
Annual Meeting Talks
2023
Intravitreal Infliximab for the Treatment of Proliferative Vitreoretinopathy Associated with Rhegmatogenous Retinal Detachment: The Phase II FIXER Trial
Ayman Elnahry, MD, PhD
Annual Meeting Talks
2023
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Week 48 Efficacy Outcomes by Baseline Demographics in the Phase 2/3 PHOTON Trial
Andres Emanuelli, MD
Annual Meeting Talks
2023
Aflibercept 8 mg for Diabetic Macular Edema: 2-Year Results of the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Annual Meeting Talks
2023